TY - JOUR
T1 - Cripto-1
T2 - An embryonic gene that promotes tumorigenesis
AU - De Castro, Nadia Pereira
AU - Rangel, Maria Cristina
AU - Nagaoka, Tadahiro
AU - Salomon, David S.
AU - Bianco, Caterina
PY - 2010/7
Y1 - 2010/7
N2 - Several studies have shown that cell fate regulation during embryonic development and oncogenic transformation share common regulatory mechanisms and signaling pathways. Indeed, an embryonic gene member of the EGF-Cripto-1/FRL1/ Cryptic family, Cripto-1, has been implicated in embryogenesis and in carcinogenesis. Cripto-1 together with the TGF- ligand Nodal is a key regulator of embryonic development and is a marker of undifferentiated human and mouse embryonic stem cells. While Cripto-1 expression is very low in normal adult tissues, Cripto-1 is re-expressed at high levels in several different human tumors, modulating cancer cell proliferation, migration, epithelial-to- mesenchymal transition and stimulating tumor angiogenesis. Therefore, inhibition of Cripto-1 expression using blocking antibodies or antisense expression vectors might be a useful modality not only to target fully differentiated cancer cells but also to target a subpopulation of tumor cells with stem-like characteristics.
AB - Several studies have shown that cell fate regulation during embryonic development and oncogenic transformation share common regulatory mechanisms and signaling pathways. Indeed, an embryonic gene member of the EGF-Cripto-1/FRL1/ Cryptic family, Cripto-1, has been implicated in embryogenesis and in carcinogenesis. Cripto-1 together with the TGF- ligand Nodal is a key regulator of embryonic development and is a marker of undifferentiated human and mouse embryonic stem cells. While Cripto-1 expression is very low in normal adult tissues, Cripto-1 is re-expressed at high levels in several different human tumors, modulating cancer cell proliferation, migration, epithelial-to- mesenchymal transition and stimulating tumor angiogenesis. Therefore, inhibition of Cripto-1 expression using blocking antibodies or antisense expression vectors might be a useful modality not only to target fully differentiated cancer cells but also to target a subpopulation of tumor cells with stem-like characteristics.
UR - http://www.scopus.com/inward/record.url?scp=77954677991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954677991&partnerID=8YFLogxK
U2 - 10.2217/fon.10.68
DO - 10.2217/fon.10.68
M3 - Review article
C2 - 20624125
AN - SCOPUS:77954677991
SN - 1479-6694
VL - 6
SP - 1127
EP - 1142
JO - Future Oncology
JF - Future Oncology
IS - 7
ER -